Thursday , December 14 2017
Home / Letter From The Editor / Letter from the Editor, #742

Letter from the Editor, #742

 

Sanofi is expanding its insulin portfolio to include the new inhaled insulin, Affreza. While it may not perform in the market at the scale of Lantus, I, for one, am glad that Sanofi is doing this.

Five years ago a small company called VeroScience came out with a new medication called Cycloset, a low-dose immediate-acting formulation of bromocriptine, for improving glucose levels. They had great study results. But because they were a small company with an almost nonexistent marketing budget, the potential of the drug remains to be realized in clinical practice because very few prescribers are aware of its significant benefits. With the marketing power of Sanofi available to spread the information, there is a good chance that Affreza will get the exposure needed to make a difference for the patients who can benefit from it.

 

*****

Announcements:
 
With a day packed full of education, motivational tools, one-on-one sessions, and workshops, the TCOYD health fair is a great way to get your patients to take better care of their health and themselves. TCOYD.com 
 
From dLife.com: "dLife investigates diabetes care in America’s prisons and jails. And, more Real People, Real Stories as we visit a woman who has a high flying way of staying fit and in control. Plus, Chef Michel Nischan gives a comfort food favorite — meatloaf — a low-carb makeover." Sundays live online at dLifeTV.com at 7 PM ET, 6 PM CT, and 4 PM PT. Keep up on the latest dLife news at dLifeTV.com.
 
*****************************

We can make a difference!
*****************************

Dave Joffe, Editor-in-chief